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Insulin signaling is a key regulator ofmetabolismand tissue growth in animals. Recentwork inCell (Hyun et al.,
2009) defines two conserved components of the insulin pathway: a microRNA and the protein USH/FOG2.The insulin/insulin-like growth factor
(IGF)-signaling pathway regulates crucial
aspects of organismal biology, including
carbohydrate metabolism, lipid metab-
olism, tissue growth, and longevity
(Grewal, 2009; Kitamura et al., 2003). As
the ‘‘Chief Financial Officer’’ of a cell,
insulin/IGF signaling gauges the environ-
ment for the availability of resources and
decides whether to be sparing or aggres-
sive with the use of these resources. It
thereby regulates the balance between
storage and breakdown of carbohydrates
and lipids, as well as the degree to which
cells grow, which is an energetically
expensive process. As a consequence,
altered insulin/IGF signaling is associated
with a number of diseases. Reduced
insulin signaling erroneously tells an
organism to conserve energy in the form
of glycogen and fat, contributing toward
diabetes and obesity. Elevated insulin
signaling spurs cell growth, contributing
to cancer development (Bjornsti and
Houghton, 2004).
Based on the importance of the insulin/
IGF pathway and on isolation of insulin
one century ago, one might expect that
by now we would have a clear under-
standing of how insulin signaling works,
and that this is all ‘‘textbook biology.’’ In
fact, this is far from true. Indeed, 40-odd
components required for insulin signaling
have been identified and characterized.
These components interact to form a
complex machine that senses the insulin
signal, processes it, and regulates cellular
physiology. Studying such a complex
machine entails identifying and under-
standing each of the parts, then under-
standing how the parts work together
as a whole, at the ‘‘system’’ level. One
century after the discovery of insulin, we
are still at step one: discovering the parts.
A recent paper in Cell from V. Narry Kim’s
lab (Hyun et al., 2009) makes a significant
contribution to this effort by describing8 Cell Metabolism 11, January 6, 2010 ª2010not just one but two novel components
of the insulin pathway (Figure 1).
Flies mutant for the microRNA (miRNA)
mir-8 exhibit malformed limbs and in-
creased neuronal apoptosis (Karres
et al., 2007). Hyun and colleagues noted
that these flies are also small in size. Since
insulin signaling regulates animal size,
they measured activation of the insulin
pathway in these flies and found that it
was reduced. Hyun et al. then observed
that miR-8 is strongly expressed in the
fly fat body, which regulates Drosophila
size. Insulin signaling in the fat body
promotes insulin signaling and growth in
other tissues of the animal via an unknown
mechanism (Ge´minard et al., 2009).
Consistent with this, Hyun et al. find that
miR-8 expression in the fat body regu-
lates the level of insulin signaling in this
tissue, consequently affecting the size of
the entire animal.
But what is the molecular mechanism
underlying miR-8 function? miRNAs are
small, regulatory RNAs that bind the 30
UTRs of target mRNAs through base-
pairing and inhibit mRNA translation by
recruiting the RISC protein complex
(Bartel, 2009). Since the miRNA/mRNA
interaction can function even with imper-
fect base-pairing, computational algo-
rithms have had difficulty identifying
in vivo mRNA targets of specific miRNAs.
To confront this problem, Hyun et al.
started with the premise that important
interactions between miR-8 and its tar-
gets should be evolutionarily conserved.
The human homologs of miR-8 are the
members of the miR-200 family. There-
fore, Hyun et al. compared the predicted
miR-8 targets in the fly with the predicted
miR-200 targets in humans and identified
the homologous gene pairs present in
both lists. Cell-culture validation of the
predictions left them with seven bona
fide miR-8 targets. By testing whether
knockdown of each of these seven genesElsevier Inc.in mir-8 mutant flies could rescue their
small body phenotype, they identified
the gene u-shaped (FOG2 in humans) as
the miR-8 target relevant for regulating
animal size.
Finally, Kim and colleagues studied
how USH/FOG2 regulates insulin sig-
naling. Upon binding insulin, the insulin
receptor becomes activated and phos-
phorylates insulin receptor substrate-1
(IRS-1) (Figure 1). This causes recruitment
and activation of the lipid kinase PI3K,
composed of a catalytic subunit, p110,
and a regulatory subunit, p85a. Hyun
et al. found that FOG2 binds p85a,
thereby inhibiting formation of the IRS-1/
p85a/p110 complex and, consequently,
PI3K activation. Expression of miR-200
causes FOG2 protein levels to drop,
allowing insulin signaling to take place.
In sum, Hyun and colleagues have iden-
tified two novel, conserved components
of the insulin-signaling pathway: miR-8/
miR-200 and USH/FOG2. This study is
interesting for a number of reasons: (1) It
illustrates how a combination of in silico
predictions and wet-lab experiments
exploiting evolutionary conservation can
successfully identify miRNA/mRNA inter-
actions of biological significance. (2) It
highlights that one miRNA can have
multiple biological effects, each one
mediated via a different target mRNA.
Whereas here USH is identified as the
miR-8 target regulating animal size, prior
work had identified atrophin as the miR-8
target regulating apoptosis in the brain
(Karres et al., 2007). Hyun et al. identify
an additional six genes that are targeted
by miR-8/miR-200, indicating likely addi-
tional functions for miR-8. (3) By identi-
fying new insulin-signaling components,
it opens the possibility of more complex
regulation of the pathway. How are ex-
pression of mir-8/mir-200 and ush/FOG2
regulated at the transcriptional level?
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Figure 1. Regulation of Insulin Signaling by miR-8/200 and USH/FOG2
Expression of mir-8 (in Drosophila) or mir-200 (in humans) represses the translation of ush (Drosophila)/FOG2 (human). As a consequence, the insulin receptor
substrate-1 (IRS-1) is free to recruit the two subunits of phosphoinositide-3 kinase (PI3K), p85a and p110, to the insulin receptor. These then become activated,
and signaling downstream of these components ensues. In the absence of mir-8/mir-200 expression, USH/FOG2 protein is produced, and it binds p85a. Forma-
tion of the IRS-1/p85a/p110 complex is attenuated, as is signaling downstream of this complex.
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Previewscell membrane is somewhat surprising,
because prior work demonstrated FOG2
to be a nuclear transcription factor. Is
the shuttling of FOG2 between cytoplasm
and nucleus regulated? (4) Since insulin
signaling is medically relevant, this study
suggests the possible involvement of
mir-8/mir-200 and ush/FOG2 in cancer
and metabolic disease should be evalu-
ated.
The insulin signaling pathway as we
currently know it consists mainly of
positively acting factors, specifically a
relay of kinases that phosphorylate and
activate each other. However, as a keyhomeostatic regulator, the insulin path-
way needs to be both activated and
inactivated. Four negatively acting com-
ponents were previously known to help
keep activation of the pathway under
control: the insulin-binding proteins,
PTEN, Tsc1/2, and PP2A. This report
adds a fifth: USH/FOG2. More are likely
to come, suggesting it may take a while
until we are done discovering all the
components of insulin signaling.REFERENCES
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